GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » Return-on-Tangible-Equity

RayzeBio (RayzeBio) Return-on-Tangible-Equity : -33.09% (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is RayzeBio Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. RayzeBio's annualized net income for the quarter that ended in Sep. 2023 was $-72.76 Mil. RayzeBio's average shareholder tangible equity for the quarter that ended in Sep. 2023 was $219.92 Mil. Therefore, RayzeBio's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2023 was -33.09%.

The historical rank and industry rank for RayzeBio's Return-on-Tangible-Equity or its related term are showing as below:

RYZB' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -30.04   Med: 0   Max: 0
Current: -30.04

RYZB's Return-on-Tangible-Equity is not ranked
in the Biotechnology industry.
Industry Median: -46.42 vs RYZB: -30.04

RayzeBio Return-on-Tangible-Equity Historical Data

The historical data trend for RayzeBio's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio Return-on-Tangible-Equity Chart

RayzeBio Annual Data
Trend Dec20 Dec21 Dec22
Return-on-Tangible-Equity
- - -

RayzeBio Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23
Return-on-Tangible-Equity Get a 7-Day Free Trial - - - - -33.09

Competitive Comparison of RayzeBio's Return-on-Tangible-Equity

For the Biotechnology subindustry, RayzeBio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RayzeBio's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RayzeBio's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where RayzeBio's Return-on-Tangible-Equity falls into.



RayzeBio Return-on-Tangible-Equity Calculation

RayzeBio's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-68.6/( (-54.574+-111.294 )/ 2 )
=-68.6/-82.934
=N/A %

RayzeBio's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-72.764/( (-135.489+575.322)/ 2 )
=-72.764/219.9165
=-33.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


RayzeBio  (NAS:RYZB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


RayzeBio Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of RayzeBio's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


RayzeBio (RayzeBio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121
RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.
Executives
Hauwermeiren Timothy Van director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi director SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p. 10 percent owner 280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song director, officer: President and Chief Executive C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran officer: Chief Medical Officer 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p. 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129